Navigation Links
Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010
Date:6/18/2010

ROCKVILLE, Md., June 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Phacilitate Vaccine Forum Barcelona 2010 conference on June 21 and June 22, 2010 at The Fira Palace, Barcelona, Spain.  Dr. Singhvi is participating in the roundtable discussion, 'Getting ready for the next influenza pandemic: How are recent experiences informing ongoing preparedness strategies?' and will also be speaking on the Case Study:  'Update on novel vaccine technologies and platforms that have been developed for the influenza market.'  

About Novavax

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology.  The company produces potent VLP-based, recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions.  In 2009, Novavax launched a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.  Additional information about Novavax is available on the company's website:

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
2. NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results
3. NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference
4. NOVAVAX to Present at Cowen and Companys 30th Annual Health Care Conference
5. NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
6. Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
7. NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock
8. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
9. Novavax to Present at 8th Annual BIO Investor Forum 2009
10. Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
11. NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015  Hill-Rom Holdings, Inc., (NYSE: HRC ) ... the Morgan Stanley Global Healthcare Conference on September 16, ... invited to listen to the live discussion via the ... at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded replay ... the conclusion of the live event and accessible via ...
(Date:8/27/2015)... The nation,s newest Actos trial gets underway Thursday, August 27 ... courtroom.  Attorneys representing two southern Nevada ... after using the diabetes drug Actos. "Takeda Pharmaceuticals ... that their drug Actos caused an increased risk of bladder ... hold Takeda responsible it is appropriate to seek substantial punitive ...
(Date:8/27/2015)...  Mytrus, a technology and services company revolutionizing clinical trials, announced ... has received approval for use by Britain,s ... first time e-Consent technology will be used in a ... Mytrus was also the first electronic informed consent ... the U.S. Food and Drug Administration in 2011. It ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... , SAN DIEGO, Oct. 26 Horizon Therapeutics, ... an analysis from two pivotal Phase 3 trials ... HZT-501, a combination of ibuprofen with high-dose famotidine. ... risk factors for the development of non-steroidal anti-inflammatory ...
... Volcano Corporation (Nasdaq: VOLC ), a leader in ... and treatment of coronary and peripheral artery disease, today announced ... quarter and first nine months of fiscal 2009 on Thursday, ... to discuss its financial results and operating activities open to ...
Cached Medicine Technology:Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 2Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 3Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 4Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2
(Date:8/27/2015)... WILMINGTON, Del. (PRWEB) , ... August 27, 2015 , ... ... Hospital, will be the guest speaker at CURE® magazine’s 3rd Annual MPN Heroes™ ... , Dr. Arnold will be among hundreds of attendees honoring eight heroes who have ...
(Date:8/27/2015)... ... August 27, 2015 , ... Healthpointe is proud to welcome ... Clinic in Los Angeles. Licensed to practice Chinese Needle Therapy since 1983, Dr. Priebe ... and diseases. Dr. Priebe also practices in Healthpointe’s La Mirada clinic and Garden Grove ...
(Date:8/27/2015)... ... August 27, 2015 , ... Banc Intranets recently entered into ... will enable both Johnson City, Tenn.-based firms to work synergistically to promote similar products ... product that caters to organizations in the financial, commercial and services sectors. The software, ...
(Date:8/27/2015)... ... August 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue ... of 2016. The new facility will be located at US Highway 19 North and Highlands ... on August 18, and work on the project is slated to begin in September 2015. ...
(Date:8/27/2015)... Downey, CA (PRWEB) , ... August 27, 2015 ... ... Oncology Institute of Hope and Innovation has grown to having twelve offices in ... in over 60 hospitals in the Southern California region. Founded by Dr. ...
Breaking Medicine News(10 mins):Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2
... to market ... final expense planning, HOUSTON, Nov. 3 ... SCI ) have formed a,unique partnership through SCI,s Dignity Memorial(TM) ... This is an extraordinary combination of services offered by two,industries ...
... Study: More Children Taking Medications for Blood Pressure, Cholesterol, ... Asthma, ADD/ADHD, Depression and Diabetes, ST. ... their use of type 2 diabetes medications between 2002 and,2005, ... a 166 percent,increase. One likely cause: Obesity, which is closely ...
... - Total revenue ... expanded to 32.4 percent from 28.5 percent ... - Net earnings: $0.8 million vs. $0.02 million - EPS: ... US: FIT), a leading provider of integrated,employee health and productivity management solutions, ...
... - Predictive medicine company,PreMD Inc. (TSX: PMD; PREMF.pk) today ... ("TSX") that it is reviewing the eligibility of the,Company,s ... The Company is being reviewed under the TSX,s Remedial ... with all requirements for continued,listing. If the Company cannot ...
... in stem cell research, experts say , , MONDAY, Nov. ... creating cloned mice from mouse bodies that had been ... feat may raise the specter of resurrecting lost species ... Teruhiko Wakayama said recreating woolly mammoths was "probably impossible." ...
... tissues in the intestinal tract that help protect the body ... immune cell newly identified by researchers at Washington University School ... immune cells could have a therapeutic role in inflammatory bowel ... Their report will appear in an upcoming issue of the ...
Cached Medicine News:Health News:SLAICO and SCI Form Partnership 2Health News:Tweens and Teens Double Use of Diabetes Drugs 2Health News:Tweens and Teens Double Use of Diabetes Drugs 3Health News:Tweens and Teens Double Use of Diabetes Drugs 4Health News:HealthFitness Announces 2008 Third Quarter Results 2Health News:HealthFitness Announces 2008 Third Quarter Results 3Health News:HealthFitness Announces 2008 Third Quarter Results 4Health News:HealthFitness Announces 2008 Third Quarter Results 5Health News:HealthFitness Announces 2008 Third Quarter Results 6Health News:HealthFitness Announces 2008 Third Quarter Results 7Health News:HealthFitness Announces 2008 Third Quarter Results 8Health News:HealthFitness Announces 2008 Third Quarter Results 9Health News:HealthFitness Announces 2008 Third Quarter Results 10Health News:Listing Review initiated by the Toronto Stock Exchange 2Health News:Scientists Make Clones of Mice Dead 16 Years 2Health News:Previously unknown immune cell may help those with Crohn's and colitis 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: